Astal Laboratories Ltd 16 Nov 2026 12:00 AM
Astal Laboratories Ltd consolidated sales up 6.93% on year in Q2FY2027, net profit inched up 3.72%,
Astal Laboratories Ltd`s net profit saw a mild growth of 3.72% to Rs 9.77 crore, while revenue from operations improved marginally 6.93% to Rs 107.94 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.76 lakh crore, rising 6.97%. It has eased by 0.66% over last one week and crept higher by 6.26% in last one month while the market capitalization of Astal Laboratories Ltd has improved by 5.27% and 22.64% in the same period respectively. Profit before tax (PBT) of Astal Laboratories Ltd stood at Rs 15.33 crore in Q2 FY27, expanding by 341.79% year-on-year, and rallying 48.12% quarter-on-quarter. EBITDA came in at Rs 17 crore, surging by 343.49% YoY and jumping 40.63% sequentially. Total expenses posted a minor rise of 2.21% to Rs 91.53 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 86.46 crore, dropping by 13.64% YoY, while employee benefits expense was at Rs 2.76 crore, tumbling by 12.38% YoY. For FY26, revenue from operations surged 287.87% to Rs 249.13 crore, while net profit soared by 64.73% to Rs 14.71 crore, compared to previous FY. EBITDA jumped by 1265% to Rs 20.55 crore, and PBT jumped 48% to Rs 17.73 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 17.7 crore in FY26, as against Rs 12.52 crore in FY25. Astal Laboratories Ltd nosedived by 33.27% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.42% during the same period.
Astal Laboratories Ltd 14 Nov 2026 12:00 AM
Astal Laboratories Ltd consolidated sales up 6.93% on year in Q2FY2027, net profit saw a mild growth of 3.72%,
Astal Laboratories Ltd`s net profit grew slightly 3.72% to Rs 9.77 crore, while revenue from operations improved marginally 6.93% to Rs 107.94 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 6.94%. It has improved by 2.52% over last one week and moved up slightly by 5.98% in last one month while the market capitalization of Astal Laboratories Ltd has inched up 4.47% and 26.80% in the same period respectively. Profit before tax (PBT) of Astal Laboratories Ltd stood at Rs 15.33 crore in Q2 FY27, surging by 341.79% year-on-year, and rallying 48.12% quarter-on-quarter. EBITDA came in at Rs 17 crore, expanding by 343.49% YoY and jumping 40.63% sequentially. Total expenses saw a slight increase of 2.21% to Rs 91.53 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 86.46 crore, dropping by 13.64% YoY, while employee benefits expense was at Rs 2.76 crore, tanking by 12.38% YoY. For FY26, revenue from operations witnessed a strong growth of 287.87% to Rs 249.13 crore, while net profit surged by 64.73% to Rs 14.71 crore, compared to previous FY. EBITDA soared by 1265% to Rs 20.55 crore, and PBT witnessed a strong rise of 48% to Rs 17.73 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 17.7 crore in FY26, as against Rs 12.52 crore in FY25. Astal Laboratories Ltd plunged by 33.27% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.42% during the same period.
Astal Laboratories Ltd 06 Nov 2026 12:00 AM
Astal Laboratories to convene board meeting November 13 to review financial results,
Astal Laboratories Limited will hold a meeting of its Board of Directors on November 13, 2026, at its corporate office in Telangana to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a Limited Review Report from the auditors. The company has closed the trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the board meeting`s conclusion, in accordance with SEBI regulations.
Astal Laboratories Ltd 14 Oct 2026 12:00 AM
Astal Laboratories confirms regulatory compliance for the quarter ended September 30, 2026,
Astal Laboratories Limited submitted a certificate to the BSE Limited on October 14, 2026, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2026. The certificate, received from BEETAL FINANCIAL & COMPUTER SERVICES (P) LTD., the company`s Registrar and Share Transfer Agent, verifies that securities received for dematerialization were confirmed to the depositories and that security certificates have been mutilated and cancelled.
Astal Laboratories Ltd 30 Sep 2026 12:00 AM
Astal Laboratories closes securities trading window for insiders ahead of results release,
Astal Laboratories Limited informed the BSE Limited that the trading window for dealing in securities of the company will be closed for all directors, officers, designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026.
Subscribe for our
newsletter
Open Account Now